Purpose: A hospital's experience with an inpatient pneumococcal vaccination program is described.
Summary: Saint Luke's Hospital (SLH) is a 625-bed, tertiary care, referral hospital in Kansas City, Missouri. In a retrospective analysis conducted in 1995 of pneumococcal vaccination rates in patients with community-acquired pneumonia (CAP) at the hospital, only 1 of 84 patients had documented pneumococcal vaccination. These results led to efforts to improve assessment of vaccination status, documentation of vaccination, and pneumococcal vaccination rates. In 1998, the pharmacy department at SLH conducted a study to examine the impact of pharmacists on pneumococcal vaccination rates through incorporation of vaccination assessment into selected critical pathways. Pharmacists were assigned to screen and educate patients on chosen pathways. When eligible patients were identified in the intervention group, the pharmacist would then contact their physician for authorization to vaccinate. The success of the study led to several notable changes to the pneumococcal vaccination program in 2001. First, the vaccination assessment was moved from selected critical pathways to the admission database of all patients. Second, a collaborative practice agreement was developed to authorize pharmacists to write pneumococcal and influenza vaccine orders for eligible patients per the program's protocol. These two changes led to a dramatic improvement in overall screening and documentation rates of pneumococcal vaccination for patients with CAP and for other at-risk patients.
Conclusion: A pneumococcal vaccination program helped a hospital meet regulatory expectations for vaccination of patients with CAP and vaccinated many other at-risk patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2146/ajhp080638 | DOI Listing |
Open Forum Infect Dis
January 2025
Harvard Medical School, Boston, Massachusetts, USA.
Background: Infections by and influenza viruses are vaccine-preventable diseases causing great morbidity and mortality. We evaluated pneumococcal and influenza vaccination practices during pre-international travel health consultations.
Methods: We evaluated data on pretravel visits over a 10-year period (1 July 2012 through 31 June 2022) from 31 sites in Global TravEpiNet (GTEN), a consortium of US healthcare facilities providing pretravel health consultations.
Epidemiol Serv Saude
January 2025
Universidade de BrasÃlia, BrasÃlia, DF, Brazil.
Objective: To estimate and compare vaccination coverage among children born in 2017-2018 in São Paulo and Campinas, according to the Vaccination Coverage Survey (ICV 2020) and the National Immunization Program Information System (SI-PNI).
Methods: ICV 2020 analyzed vaccination card records. Coverage was calculated and compared to doses recorded on the SI-PNI, divided by the target population.
BMC Pediatr
January 2025
Department of Medical Laboratory Sciences, School of Allied Health Sciences, Kampala International University Western Campus, P. O. Box 71, Bushenyi, Uganda.
In spite of the commendable global Pneumococcal Conjugate Vaccine (PCV) coverage in the last two decades, completion and timeliness of receipt of all the required doses are still below target. In Uganda, the 3 + 0 PCV regimen has been reported to have a steady decline in the completion rate and the reasons for the delayed completion are unidentified. This study aimed at assessing the influence of socio-demographic factors on delayed PCV completion among young children.
View Article and Find Full Text PDFHerz
January 2025
Klinik für Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str. 1, 66421, Homburg/Saar, Deutschland.
Respiratory tract infections with influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and respiratory syncytial (RS) viruses and pneumococci as well as endogenous reactivation of varicella zoster viruses presenting as herpes zoster, are associated with adverse cardiovascular outcomes, such as myocardial infarction or hospitalization for heart failure. Effective prevention of these events, particularly through influenza and pneumococcal vaccination, is well established and cost-effective. Despite guideline recommendations to vaccinate older patients and people at risk, vaccination rates in these population groups remain suboptimal and below average in international comparison.
View Article and Find Full Text PDFZhonghua Yi Xue Za Zhi
January 2025
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing102206, China.
Pneumococcal disease (PD) caused by (Sp) is a global public health concern. Children younger than 5 years and elderly over 60 years, due to immature development of the immune system early in life or the gradual decline of immune function with age, are high-risk groups for pneumococcal infections, which makes the disease burden particularly serious and the situation of prevention and control grim. Vaccination is the most effective measure to prevent PD and reduce pneumococcal antimicrobial resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!